Background Patent ductus arteriosus (PDA) causes increased pulmonary blood flow, which
can lead to pulmonary arterial hypertension (PAH). Rho-associated coiled-coil containing …

Background Congenital atrial septal defect (ASD) causes increased pulmonary blood flow,
which can lead to pulmonary arterial hypertension (PAH). Rho kinase (ROCK) may play an …

Background-At birth, functional closure of the ductus arteriosus (DA) is initiated within
minutes by inhibition of oxygen-sensitive, voltage-gated K+ channels. The resulting …

Objective To investigate the risk factors for thrombocytopenia after transcatheter occlusion
operation of patent ductus arteriosus (PDA). Method Retrospective analyses were …

Objectives To observe the change in pulmonary artery systolic pressure (PASP) of patients
with persistent pulmonary arterial hypertension (PAH) after patent ductus arteriosus (PDA) …

Objective High pulmonary blood flow induced pulmonary hypertension (PH) is often
associated with increased vasoconstriction and deteriorating pulmonary artery remodeling …

Aim To evaluate the immediate and follow-up results of transcatheter closure of large PDAs
with severe pulmonary arterial hypertension (PAH) in adults. Method After a complete …

Objective To determine effects of the RhoA/Rho kinase signaling pathway on patients with
pulmonary arterial hypertension related to chronic obstructive pulmonary diseases by testing …

Background Transcatheter closure of patent ductus arteriosus (PDA) is a well established
procedure and an accepted treatment modality for small to moderate-sized PDA. This study …

(1) Background: the indications for transcatheter closure of large patent ductus arteriosus
(PDA) with severe pulmonary hypertension (PH) are still unclear, and scholars have not fully …